SHOCKING: Astrazeneca - You Need To See This

Ultomiris Wins Accelerated FDA Approval for IgA Nephropathy After Trial Showed 43% Greater Drop in Urine Protein

FDA granted Ultomiris accelerated approval for IgA nephropathy based on lower urine protein. What it means and the infection risks to know.

Medical Daily · Oct 23

Nearly Two in Three Eosinophilic Esophagitis Patients on Tezspire Reached Tissue Remission After One Year of Treatment

In a Phase 3 trial, Tezspire put most eosinophilic esophagitis patients in tissue remission at one year. What does it mean for swallowing and approval?

Medical Daily · Oct 21

AstraZeneca strikes $40 million AI drug discovery deal with insitro

AstraZeneca has entered a collaboration with insitro to explore new treatment options for challenging liver and heart diseases. The partnership involves a $40 million upfront payment and potential milestones totaling approximately $1.46 billion. Insitro will utilize its AI platform to identify biological drivers for metabolic dysfunction-associated steatohepatitis and cardiomyopathies. Following…

The Economic Times · Oct 15

AstraZeneca invests £1.5bn into US firm Summit for cancer drug tie-up

The firms will collaborate on Summit’s experimental new medicine as well as researching how it could be combined with Astra’s treatments.

Evening Standard · Sep 29

UK government pays highest interest rate on 10-year debt since 1999 at bond auction – as it happened

Rolling coverage of the latest economic and financial news

The Guardian - UK · Sep 29

Tumor Genetic Tests Point Rare Cancer Patients Toward Off-Label Drugs That Insurers Often Refuse to Cover

Tumor genetics can point to a drug approved for another cancer, but insurers often refuse to pay. What rare cancer patients can do.

Medical Daily · Sep 25

European drugmakers say they are ‘losing ground’ to US and Chinese rivals

Some of continent’s biggest pharma firms write to national leaders calling for action to safeguard the sector

The Guardian - UK · Sep 22

Global Market: European shares rise as oil slide boosts risk appetite

European shares rose as technology stocks led gains and falling oil prices eased inflation concerns. The STOXX 600 advanced 0.56%, while investors also tracked the upcoming Trump-Xi meeting.

The Economic Times · Sep 21

Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugs

Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating diversification into new therapy areas for sustainable growth. With Eli Lilly set to outshine its sales figures this year, analysts suggest a pivot towards developing zenagamtide instead of CagriSema. It is…

The Economic Times · Sep 21

First-Line Enhertu Delayed HER2-Mutant Lung Cancer Progression by Six Months Over Keytruda Plus Chemotherapy, but Survival Remains Unsettled

Enhertu delayed HER2-mutant lung cancer progression by a median of six months versus Keytruda plus chemo in a Phase 3 trial. Survival is unresolved.

Medical Daily · Sep 17